Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11200681 | 0.91 | L3MBTL1 (0.76) | L3MBTL1HRH3ACACBMAPK1KMT2A | |
| SCHEMBL11010729 | 0.87 | L3MBTL1 (0.58) | L3MBTL1HRH3ACACBMAPK1KMT2A | |
| SCHEMBL632892 | 0.86 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBMAPK1KMT2A | |
| Hydrochloric Acid SCHEMBL2312230 | 0.85 | L3MBTL1 (0.59) | L3MBTL1HRH3ACACBMAPK1KMT2A | |
| SCHEMBL10399987 | 0.84 | L3MBTL1 (0.67) | L3MBTL1HRH3ACACBKMT2AGRIA2 | |
| SCHEMBL19717008 | 0.84 | L3MBTL1 (0.67) | L3MBTL1HRH3ACACBMAPK1KMT2A | |
| SCHEMBL10719943 | 0.83 | L3MBTL1 (0.58) | L3MBTL1HRH3ACACBMAPK1KMT2A | |
| SCHEMBL12387514 | 0.83 | L3MBTL1 (0.66) | L3MBTL1HRH3ACACBMAPK1KMT2A | |
| SCHEMBL256037 | 0.82 | L3MBTL1 (0.65) | L3MBTL1HRH3ACACBMAPK1KMT2A | |
| SCHEMBL2223756 | 0.82 | L3MBTL1 (0.70) | L3MBTL1HRH3ACACBMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0136658-A2 | -1-Benzyl-aminoalkyl-pyrrolidinones and their addition salts, process for their preparation and pharmaceutical compounds containing them | BOEHRINGER INGELHEIM KG (DE) | 1985-04-10 | — | — | EP | claimed |
| WO-2023177700-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-3177611-B1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION AS (DK) | 2021-10-06 | — | — | EP | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | NUEVOLUTION A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-16 | — | — | US | disclosed |
| EP-1379236-A4 | TREATMENT OF TICS, TREMORS AND RELATED DISORDERS | UCB SA (BE) | 2009-01-21 | — | — | EP | disclosed |
| EP-1732561-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| EP-1379236-A1 | TREATMENT OF TICS, TREMORS AND RELATED DISORDERS | The Johns Hopkins University (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002067931-A1 | TREATMENT OF TICS, TREMORS AND RELATED DISORDERS | JOHNS HOPKINS UNIVERSITY (US) | 2002-09-06 | — | — | WO | disclosed |
| US-4996224-A | 1-benzyl-4- or 5-pyrrolidinomethyl-pyrrolidin-2-ones and nootropic method of use thereof | BOEHRINGER INGELHEIM KG (DE) | 1991-02-26 | — | — | US | disclosed |
| EP-0163260-A1 | Novel substituted pyrrolidinones, process for their manufacture and pharmaceutics | BOEHRINGER INGELHEIM KG (DE) | 1985-12-04 | — | — | EP | disclosed |
| EP-0136658-A2 | -1-Benzyl-aminoalkyl-pyrrolidinones and their addition salts, process for their preparation and pharmaceutical compounds containing them | BOEHRINGER INGELHEIM KG (DE) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689383-B2 | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases | RORA, RORC, RORB | L3MBTL1 4748/4885HRH3 366/4885ACACB 631/4885 |
| US-20170327503-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | L3MBTL1 4725/4885HRH3 730/4885ACACB 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.